127 related articles for article (PubMed ID: 12775573)
1. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose.
Bachar-Lustig E; Reich-Zeliger S; Reisner Y
Blood; 2003 Sep; 102(6):1943-50. PubMed ID: 12775573
[TBL] [Abstract][Full Text] [Related]
2. Overcoming T cell-mediated rejection of bone marrow allografts by T-regulatory cells: synergism with veto cells and rapamycin.
Steiner D; Brunicki N; Bachar-Lustig E; Taylor PA; Blazar BR; Reisner Y
Exp Hematol; 2006 Jun; 34(6):802-8. PubMed ID: 16728286
[TBL] [Abstract][Full Text] [Related]
3. Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation.
Aviner S; Yao X; Krauthgamer R; Gan Y; Goren-Arbel R; Klein T; Tabilio A; McMannis JD; Champlin R; Martelli MF; Bachar-Lustig E; Reisner Y
Hum Immunol; 2005 Jun; 66(6):644-52. PubMed ID: 15993710
[TBL] [Abstract][Full Text] [Related]
4. Tolerance induction in presensitized bone marrow recipients by veto CTLs: effective deletion of host anti-donor memory effector cells.
Reich-Zeliger S; Bachar-Lustig E; Bar-Ilan A; Reisner Y
J Immunol; 2007 Nov; 179(10):6389-94. PubMed ID: 17982025
[TBL] [Abstract][Full Text] [Related]
5. Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. I. Relative reactivity of different veto cells.
Reich-Zeliger S; Bachar-Lustig E; Gan J; Reisner Y
J Immunol; 2004 Dec; 173(11):6654-9. PubMed ID: 15557156
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells.
Reisner Y; Gur H; Reich-Zeliger S; Martelli MF; Bachar-Lustig E
Ann N Y Acad Sci; 2003 May; 996():72-9. PubMed ID: 12799285
[TBL] [Abstract][Full Text] [Related]
7. Murine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.
Ophir E; Or-Geva N; Gurevich I; Tal O; Eidelstein Y; Shezen E; Margalit R; Lask A; Shakhar G; Hagin D; Bachar-Lustig E; Reich-Zeliger S; Beilhack A; Negrin R; Reisner Y
Blood; 2013 Feb; 121(7):1220-8. PubMed ID: 23223359
[TBL] [Abstract][Full Text] [Related]
8. Anti-third party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite.
Reich-Zeliger S; Zhao Y; Krauthgamer R; Bachar-Lustig E; Reisner Y
Immunity; 2000 Oct; 13(4):507-15. PubMed ID: 11070169
[TBL] [Abstract][Full Text] [Related]
9. Transplantation of Graft Anti-Host Cytotoxic T Lymphocytes Along with Allogeneic Bone Marrow Skips Macrophage-Induced Graft-Versus-Host Disease.
Yoshida R; Yamana H; Hayashi M; Yasuda E; Shibayama Y; Hirose Y; Tanigawa N; Uchiyama K; Kubota T
J Interferon Cytokine Res; 2021 Sep; 41(9):310-318. PubMed ID: 34543129
[TBL] [Abstract][Full Text] [Related]
10. Eradication of B-CLL by autologous and allogeneic host nonreactive anti-third-party CTLs.
Arditti FD; Aviner S; Dekel B; Krauthgamer R; Gan J; Nagler A; Tabilio A; Martelli M; Berrebi A; Reisner Y
Blood; 2005 Apr; 105(8):3365-71. PubMed ID: 15238417
[TBL] [Abstract][Full Text] [Related]
11. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation.
Uberti J; Martilotti F; Chou TH; Kaplan J
Blood; 1992 Jan; 79(1):261-8. PubMed ID: 1370206
[TBL] [Abstract][Full Text] [Related]
12. Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.
Ophir E; Eidelstein Y; Afik R; Bachar-Lustig E; Reisner Y
Blood; 2010 Mar; 115(10):2095-104. PubMed ID: 20042725
[TBL] [Abstract][Full Text] [Related]
13. Tolerance induction by third-party "off-the-shelf" CD4+CD25+ Treg cells.
Steiner D; Brunicki N; Blazar BR; Bachar-Lustig E; Reisner Y
Exp Hematol; 2006 Jan; 34(1):66-71. PubMed ID: 16413392
[TBL] [Abstract][Full Text] [Related]
14. Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy.
Bachar-Lustig E; Lask A; Eidelstein Y; Or-Geva N; Gidron-Budovsky R; Nathansohn-Levy B; Eyrich M; Liu WH; Dang G; Miranda KC; Ramirez A; Kaur I; Rezvani K; Shpall E; Champlin RE; Nagler A; Shimoni A; Barnees-Kagan S; Reisner Y
Transplant Cell Ther; 2024 Jan; 30(1):71.e1-71.e13. PubMed ID: 37890590
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mixed lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity.
Pierce GE
Transplantation; 1990 Jan; 49(1):138-44. PubMed ID: 2137269
[TBL] [Abstract][Full Text] [Related]
16. Methyl-Guanine-Methyl-Transferase Transgenic Bone Marrow Transplantation Allows N,N-bis(2-chloroethyl)-Nitrosourea Driven Donor Mixed-Chimerism Without Graft-Versus-Host Disease, and With Donor-Specific Allograft Tolerance.
Hu M; Kramer B; Zhang GY; Wang YM; Watson D; Howden B; McCowage G; Alexander IE; Gunning P; Alexander SI
Transplantation; 2015 Dec; 99(12):2476-84. PubMed ID: 26177088
[TBL] [Abstract][Full Text] [Related]
17. Crossing the HLA barriers.
Reisner Y; Gur H; Reich-Zeliger S; Martelli MF; Bachar-Lustig E
Blood Cells Mol Dis; 2004; 33(3):206-10. PubMed ID: 15528132
[TBL] [Abstract][Full Text] [Related]
18. Induction of tolerance in organ recipients by hematopoietic stem cell transplantation.
Ophir E; Reisner Y
Int Immunopharmacol; 2009 Jun; 9(6):694-700. PubMed ID: 19150657
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells.
Reisner Y; Gur H; Reich-Zeliger S; Martelli MF; Bachar-Lustig E
Ann N Y Acad Sci; 2005 Jun; 1044():70-83. PubMed ID: 15958699
[TBL] [Abstract][Full Text] [Related]
20. Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen.
Dodd-O JM; Ganguly S; Vulic A; Panoskaltsis-Mortari A; McDyer JF; Luznik L
Transplantation; 2016 Dec; 100(12):e140-e146. PubMed ID: 27861294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
